An overview of abuse-deterrent opioids and recommendations for practical patient care

References

• PaulozziLJVital signs: overdoses of prescription opioid pain relievers – United States, 1999–2008MMWR Morb Mortal Wkly Rep2011601487149222048730
   PubMedGoogle Scholar
• National Institute on Drug Abuse Overdose death rates2017 Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-ratesAccessed February 6, 2018
   Google Scholar
• Centers for Disease Control and Prevention, National Center for Health StatisticsMultiple Cause of Death 1999–2016 on CDC WONDER Online Database, released December, 2017Data are from the Multiple Cause of Death Files, 1999–2016 as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program Accessed from: https://wonder.cdc.gov/controller/saved/D77/D38F188Accessed April 13, 2018
   Google Scholar
• AhmadFBRossenLMSpencerMRProvisional drug overdose death countsNational Center for Health Statistics2018 Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htmAccessed February 19, 2018
   Google Scholar
• SmithSMDartRCKatzNPClassification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendationsPain20131542287229623792283
   PubMed Web of Science ®Google Scholar
• Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52)Rockville, MD2017 Available from: https://store.samhsa.gov/shin/content//SMA17-5044/SMA17-5044.pdfAccessed December 7, 2017
   Google Scholar
• FlorenceCSZhouCLuoFThe economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013Med. Care20165490190627623005
   PubMed Web of Science ®Google Scholar
• HallAJLJToblinRLKaplanJAPatterns of abuse among unintentional pharmaceutical overdose fatalitiesJ Am Med Assoc200830026132620
   PubMed Web of Science ®Google Scholar
• BinswangerIAGlanzJMPharmaceutical opioids in the home and youth: implications for adult medical practiceSubst Abus20153614114325671706
   PubMed Web of Science ®Google Scholar
• BlackhallLJAlfsonEDBarclayJSScreening for substance abuse and diversion in Virginia hospicesJ Palliat Med20131623724223289944
   PubMed Web of Science ®Google Scholar
• AlexanderLWeingartenBA pharmacist’s guide to the emerging abuse deterrence technology used in opioid analgesicsPharmacy Times201481–4
   Google Scholar
• PaulozziLJSenate Health Committee: trends in unintentional drug overdose deaths 2008 Available from: https://www.judiciary.senate.gov/imo/media/doc/paulozzi_testimony_03_12_08.pdfAccessed January 5, 2018
   Google Scholar
• GasiorMBondMMalamutRRoutes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulationsPostgrad Med2016128859626566680
   PubMed Web of Science ®Google Scholar
• GreenJLBucher BartelsonBLe LaitMCMedical outcomes associated with prescription opioid abuse via oral and non-oral routes of administrationDrug Alcohol Depend201717514014528414990
   PubMed Web of Science ®Google Scholar
• BudmanSHGrimes SerranoJMButlerSFCan abuse deterrent formulations make a difference? Expectation and speculationHarm Reduct J20096819480676
   PubMed Web of Science ®Google Scholar
• LankenauSETetiMSilvaKInitiation into prescription opioid misuse amongst young injection drug usersInt J Drug Policy201223374421689917
   PubMed Web of Science ®Google Scholar
• YewellJHaydonRArcherSComplications of intranasal prescription narcotic abuseAnn Otol Rhinol Laryngol200211117417711860072
   PubMed Web of Science ®Google Scholar
• Department US of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Abuse-deterrent opioids – evaluation and labeling: guidance for industrySilver Spring, MDU.S. Department of Health and Human Services2015 Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdfAccessed December 7, 2017
   Google Scholar
• OxyContin®(oxycodone hydrocodone) extended-release [package insert] Stamford, CTPurdue Pharma, L.P.2015
   Google Scholar
• HaleMEMoeDBondMAbuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer painPain Manag2016649750827050830
   PubMed Web of Science ®Google Scholar
• HarrisSCPerrinoPJSmithIAbuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid usersJ Clin Pharmacol20145446847724243216
   PubMed Web of Science ®Google Scholar
• DartRCSurrattHLCiceroTJTrends in opioid analgesic abuse and mortality in the United StatesN Engl J Med201537224124825587948
   PubMed Web of Science ®Google Scholar
• SellersEMPerrinoPJColucciSVAttractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potentialJ Psychopharmacol20132780881623784739
   PubMed Web of Science ®Google Scholar
• Hysingla™ER(hydrocodone bitartrate) extended-release tablets [package insert]Stamford, CTPurdue Pharma L.P.2014
   Google Scholar
• HarrisSCCiprianoAColucciSVOral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid usersPain Med2017181278129127651514
   PubMed Web of Science ®Google Scholar
• HarrisSCCiprianoAColucciSVIntranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid usersPain Med20161782083126814240
   PubMed Web of Science ®Google Scholar
• MorphaBond™ER(morphine sulfate) extended-release tablets [package insert]Basking Ridge, NJDaiichi Sankyo, Inc.2017
   Google Scholar
• WebsterLRPantaleonCShahMSA randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine-morphine ARERPain Med2017181303131327651506
   PubMed Web of Science ®Google Scholar
• Xtampza^® ER (oxycodone) extended-release capsules [package insert]Canton, MACollegium Pharmaceutical, Inc.2016
   Google Scholar
• KopeckyEAFlemingABLevy-CoopermanNOral human abuse potential of oxycodone DETERx® (Xtampza® ER)J Clin Pharmacol20175750051227669664
   PubMed Web of Science ®Google Scholar
• WebsterLRKopeckyEASmithMDA randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodonePain Med2016171112113026814256
   PubMed Web of Science ®Google Scholar
• Arymo™ER(morphine sulfate) extended-release tablets [package insert]Wayne, PAEgalet Corporation2017
   Google Scholar
• SmithMDWebsterLRLawlerJHuman abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (morphine-ADER injection-molded tablets) versus extended-release morphine administered orally in nondependent recreational opioid usersPain Med20171889890727633773
   PubMed Web of Science ®Google Scholar
• WebsterLRSmithMDLawlerJHuman abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (morphine-ADER injection-molded tablets) vs extended-release morphine administered intranasally in nondependent recreational opioid usersPain Med2017181695170527651510
   PubMed Web of Science ®Google Scholar
• Embeda®(morphine sulfate and naltrexone hydrochloride) extended-release capsules [package insert]New York, NYPfizer Inc.2014
   Google Scholar
• SetnikBRolandCLGoliVA clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patientsJ Opioid Manag2013913915023709323
   PubMedGoogle Scholar
• SetnikBSommervilleKGoliVAssessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid usersPain Med2013141173118623745947
   PubMed Web of Science ®Google Scholar
• StaufferJSetnikBSokolowskaMSubjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover studyClin Drug Investig200929777790
   PubMed Web of Science ®Google Scholar
• SetnikBGoliVLevy-CoopermanNAssessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid usersPain Res Manag201318e55e6223936895
   PubMed Web of Science ®Google Scholar
• WebsterLRJohnsonFKStaufferJImpact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid usersDrugs R D20111125927521902287
   PubMedGoogle Scholar
• FarberRRaeSThis week in FDA vs Biotech Part I, Will Teva’s Vantrela get abuse-deterrent label?Market Exclusive: Weekly Biotech Report2016 Available from: https://marketexclusive.com/weekly-biotech-report-covering-vantrela/2016/06/Accessed June 26, 2017
   Google Scholar
• Vantrela™ ER package insert (hydrocodone bitartrate) extended-release tablets [package insert]North Wales, PATeva Pharmaceuticals2017
   Google Scholar
• Targiniq™ER(oxycodone hydrochloride and naloxone hydrochloride) extended-release tablets [package insert]Stamford, CTPurdue Pharma L.P2016
   Google Scholar
• Troxyca®ER(oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules [package insert]New York, NYPfizer, Inc2016
   Google Scholar
• RoxyBond™ (oxycodone hydrochloride) tablets [package insert]Morristown, NJInspirion Delivery Sciences, LLC2017
   Google Scholar
• WebsterLRMarkmanJConeEJCurrent and future development of extended-release, abuse-deterrent opioid formulations in the United StatesPostgrad Med201712910211027915497
   PubMed Web of Science ®Google Scholar
• ChilcoatHDCoplanPMHarikrishnanVDecreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)Drug Alcohol Depend201616522122827372220
   PubMed Web of Science ®Google Scholar
• CoplanPMKaleHSandstromLChanges in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristicsPharmacoepidemiol Drug Saf2013221274128224123484
   PubMed Web of Science ®Google Scholar
• SevertsonSGEllisMSKurtzSPSustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodoneDrug Alcohol Depend201616821922927716575
   PubMed Web of Science ®Google Scholar
• RadnovichRChapmanCRGudinJAAcute pain: effective management requires comprehensive assessmentPostgrad Med20141265972
   PubMed Web of Science ®Google Scholar
• ManchikantiLKayeAMKnezevicNNResponsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) GuidelinesPain Physician201720S3S9228226332
   PubMed Web of Science ®Google Scholar
• ChouRFanciulloGJFinePGClinical guidelines for the use of chronic opioid therapy in chronic noncancer painJ Pain20091011313019187889
   PubMed Web of Science ®Google Scholar
• DowellDHaegerichTMChouRCDC Guideline for prescribing opioids for chronic pain – United States, 2016MMWR Recomm Rep201665149
   PubMed Web of Science ®Google Scholar
• KayeADJonesMRKayeAMPrescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (Part 2)Pain Physician201720S111S13328226334
   PubMed Web of Science ®Google Scholar
• PancariJBairdCManaging prescription drug diversion risks: caring for individuals at homeJ Addict Nurs20142511412125202807
   PubMed Web of Science ®Google Scholar
• SetnikBRolandCLGoliVSelf-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States cityJ Opioid Manag20151146347326728643
   PubMedGoogle Scholar
• LewisETCucciareMATraftonJAWhat do patients do with unused opioid medications?Clin J Pain20143065466224281287
   PubMed Web of Science ®Google Scholar
• YanovitzkyIA multiyear assessment of public response to a statewide drug take-back and disposal campaign, 2010 to 2012Health Educ Behav20174459059728718353
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic ReviewAbuse-deterrent opioids: final evidence report2017 Available from: https://icer-review.org/material/adf-final-report/Accessed November 27, 2017
   Google Scholar
• TetraultJJLBNon-medical prescription opioid use and prescription opioid use disorder: a reviewYale J Biol Med20158822723326339205
   PubMedGoogle Scholar